AU2018262698B2 - Expansion of gamma delta T cells, compositions, and methods of use thereof - Google Patents

Expansion of gamma delta T cells, compositions, and methods of use thereof Download PDF

Info

Publication number
AU2018262698B2
AU2018262698B2 AU2018262698A AU2018262698A AU2018262698B2 AU 2018262698 B2 AU2018262698 B2 AU 2018262698B2 AU 2018262698 A AU2018262698 A AU 2018262698A AU 2018262698 A AU2018262698 A AU 2018262698A AU 2018262698 B2 AU2018262698 B2 AU 2018262698B2
Authority
AU
Australia
Prior art keywords
cells
population
expanded
cell
haematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018262698A
Other languages
English (en)
Other versions
AU2018262698A1 (en
Inventor
Richard Beatson
Adrian HAYDAY
Maria Luisa IANNITTO
Natalie MOUNT
Oliver Nussbaumer
Richard Woolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
GammaDelta Therapeutics Ltd
Original Assignee
King's College London
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London, GammaDelta Therapeutics Ltd filed Critical King's College London
Publication of AU2018262698A1 publication Critical patent/AU2018262698A1/en
Application granted granted Critical
Publication of AU2018262698B2 publication Critical patent/AU2018262698B2/en
Priority to AU2025230679A priority Critical patent/AU2025230679A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2333—Interleukin-33 (IL-33)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018262698A 2017-05-03 2018-05-03 Expansion of gamma delta T cells, compositions, and methods of use thereof Active AU2018262698B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025230679A AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707048.3 2017-05-03
GBGB1707048.3A GB201707048D0 (en) 2017-05-03 2017-05-03 Expansion of gamma delta cells, compositions, and methods of use thereof
PCT/EP2018/061413 WO2018202808A2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025230679A Division AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2018262698A1 AU2018262698A1 (en) 2019-12-12
AU2018262698B2 true AU2018262698B2 (en) 2025-07-03

Family

ID=59010925

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018262698A Active AU2018262698B2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta T cells, compositions, and methods of use thereof
AU2025230679A Pending AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025230679A Pending AU2025230679A1 (en) 2017-05-03 2025-09-10 Expansion of gamma delta T cells, compositions, and methods of use thereof

Country Status (14)

Country Link
US (3) US11655453B2 (cg-RX-API-DMAC7.html)
EP (1) EP3619298A2 (cg-RX-API-DMAC7.html)
JP (3) JP2020518289A (cg-RX-API-DMAC7.html)
KR (2) KR20250080907A (cg-RX-API-DMAC7.html)
CN (1) CN110914410A (cg-RX-API-DMAC7.html)
AU (2) AU2018262698B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019023076A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062386A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992610A1 (cg-RX-API-DMAC7.html)
GB (1) GB201707048D0 (cg-RX-API-DMAC7.html)
IL (3) IL270365B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019013001A (cg-RX-API-DMAC7.html)
PH (1) PH12019502485A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018202808A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201818243D0 (en) * 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
KR20210111746A (ko) 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
GB201909144D0 (en) * 2019-06-25 2019-08-07 Autolus Ltd Culture medium
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
IL293459A (en) * 2019-12-03 2022-07-01 Adicet Bio Inc Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
WO2021186137A1 (en) 2020-03-20 2021-09-23 GammaDelta Therapeutics Limited V delta1+ t cells for the treatment of myeloid malignancies
GB202006989D0 (en) 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
GB202013962D0 (en) * 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
CN113234675A (zh) * 2021-03-31 2021-08-10 广西医科大学 一种γδT细胞以及采用体外制备γδT细胞的方法
GB202105113D0 (en) * 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
WO2022221439A1 (en) * 2021-04-14 2022-10-20 The Trustees Of The University Of Pennsylvania Methods to determine treatment efficacy with gamma-delta t cells
AU2022258567B2 (en) * 2021-04-16 2026-06-18 Acepodia Biotechnologies Ltd. Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof
WO2023069322A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
JP2025504363A (ja) * 2022-01-05 2025-02-12 インヒブルクス バイオサイエンシズ インコーポレイテッド γδT細胞結合ポリペプチド及びその使用
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2025017531A1 (en) 2023-07-20 2025-01-23 Takeda Pharmaceutical Company Limited Grid-free methods for making gamma delta t cells
JP2026526851A (ja) * 2023-07-26 2026-08-10 ヤンセン バイオテツク,インコーポレーテツド 細胞増殖のための材料及び方法
WO2026096605A1 (en) * 2024-10-31 2026-05-07 Pointloma Biosciences, Inc. Methods for activation and expansion of gamma delta t cells
WO2026110042A1 (en) * 2024-11-19 2026-05-28 King's College London Methods of expansion of skin vdelta1+ gammadelta t cells and use of same
KR20260090785A (ko) * 2024-12-09 2026-06-17 한국과학기술원 체내 지속성 및 항종양 효과가 향상된 세포치료제, 및 이의 제조방법
WO2026133284A1 (en) 2024-12-19 2026-06-25 Takeda Pharmaceutical Company Limited Methods of expanding and production of gammadelta t cells
EP4779306A1 (en) * 2025-01-17 2026-07-22 HUB Organoids IP B.V. Co-cultures of organoids, stromal cells and immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189356A1 (en) * 2014-06-11 2015-12-17 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2016198480A1 (en) * 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
NZ511760A (en) 1998-11-04 2003-10-31 Hemosol Inc Methods for the production of TcR gamma delta T cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
ES2539845B1 (es) 2013-08-05 2016-04-13 Universidad De Alicante Procedimiento y síntesis de monolitos de carbón activo a partir de cascarilla de cacao
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
US11150242B2 (en) * 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189356A1 (en) * 2014-06-11 2015-12-17 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2016198480A1 (en) * 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHING-LIANG CHU ET AL: "Differential Effects of IL-2 and IL-15 on the Death and Survival of Activated TCRgd1 Intestinal Intraepithelial Lymphocytes1", THE JOURNAL OF IMMUNOLOGY, 15 February 1999 (1999-02-15), pages 1896 - 1903 *
V. CHENNUPATI ET AL: "Intra- and Intercompartmental Movement of T Cells", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 9, 24 September 2010 (2010-09-24), pages 5160 - 5168 *
WOOLF RICHARD ET AL: "Potential for innate-like responsiveness of resident T cells in human skin: a new perspective on tissue immune-surveillance", THE LANCET (LETTERS TO THE EDITOR), vol. 387, 25 February 2016 (2016-02-25), pages 108 - 108 *

Also Published As

Publication number Publication date
PH12019502485A1 (en) 2021-01-04
IL270365B1 (en) 2024-06-01
MX2019013001A (es) 2021-01-20
JP7698672B2 (ja) 2025-06-25
WO2018202808A2 (en) 2018-11-08
AU2018262698A1 (en) 2019-12-12
EA201992610A1 (ru) 2020-04-23
CA3062386A1 (en) 2018-11-08
IL270365B2 (en) 2024-10-01
JP2025134795A (ja) 2025-09-17
US20210087528A1 (en) 2021-03-25
AU2025230679A1 (en) 2025-10-02
CN110914410A (zh) 2020-03-24
BR112019023076A2 (pt) 2020-06-09
IL312633B2 (en) 2025-08-01
GB201707048D0 (en) 2017-06-14
MX2024004897A (es) 2024-05-07
US20230242878A1 (en) 2023-08-03
EP3619298A2 (en) 2020-03-11
WO2018202808A3 (en) 2019-01-03
KR20250080907A (ko) 2025-06-05
WO2018202808A9 (en) 2019-03-07
IL312633A (en) 2024-07-01
US20260174861A1 (en) 2026-06-25
US12458698B2 (en) 2025-11-04
KR20200024770A (ko) 2020-03-09
JP2020518289A (ja) 2020-06-25
KR102812405B1 (ko) 2025-05-23
US11655453B2 (en) 2023-05-23
IL270365A (cg-RX-API-DMAC7.html) 2019-12-31
JP2023058687A (ja) 2023-04-25
IL312633B1 (en) 2025-04-01
IL319114A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
US12458698B2 (en) Expansion of γδ T cells, compositions, and methods of use thereof
US20230099491A1 (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
HK40090397A (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
BR122025001918A2 (pt) Métodos de expansão de células t gama delta, composições, seu uso e uso de células t gama delta expandidas
EA049808B1 (ru) ЭКСПАНСИЯ γΔ-Т-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA044224B1 (ru) ЭКСПАНСИЯ γδ-T-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK1253954B (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)